EBE announces the appointment of Michele Antonelli as Vice-President
Brussels, 14 May 2019 – The European Biopharmaceutical Enterprises (EBE) is pleased to announce the appointment of Mr Michele Antonelli, Chief Executive Officer of Stallergenes Greer, as EBE Vice-President. Mr Antonelli succeeds to François Martelet, ex-Chief Executive Officer NetScientific, who served as EBE Vice President from June 2018 until end April 2019.
Mr Antonelli is a member of the EBE Board of Directors since June 2016. He has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in manufacturing, commercial and general management.
Mr Antonelli joined Stallergenes Greer in November 2015 as Executive Vice President, Head of International Operations. In February 2016, Mr Antonelli was appointed Executive Vice President, Head of Europe and International, overseeing both commercial and technical operations for the Company’s Europe and International region. During the same period he also served as President of Stallergenes SAS. In January 2019, Mr Antonelli was appointed Chief Executive Officer of Stallergenes Greer.
Prior to Stallergenes Greer, Mr Antonelli worked at UCB, the multinational biopharmaceutical company, as an Executive Committee Member where he held roles of various responsibility and scope in Belgium, Italy and France, most recently serving as Executive Vice President and Head of Immunology Europe, overseeing the region’s commercial, medical and market access activities. Prior to joining UCB, Mr Antonelli spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development. He is Swiss and Italian, and graduated as Doctor in Sciences from the University of Bari. He trained in Biotechnology at Catholic University in Piacenza and at Iowa State University in Ames, Iowa.
«I am thrilled to announce that Dr Michele Antonelli, Chief Executive Officer of Stallergenes Greer, has accepted to become the new Vice-President of the EBE. Michele’s understanding of the biopharmaceutical field will help us to achieve our long-term vision. I also would like to thank François Martelet for his great contribution over the past year», stated Ahmed Bouzidi, EBE President.
«I am honored to serve EBE in this new role and to continue to drive forward the association’s strategic focus on emerging sciences and advanced technologies to benefit patients across Europe. This is an exciting time for the European biopharmaceutical sector and I look forward to helping our industry support innovation through new therapies within an evolving regulatory framework”, stated Michele Antonelli, EBE Vice-President ».
The European Biopharmaceutical Enterprises (EBE), a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. It has 50 member companies – majority of which are small and medium sized companies – engaged in the research, development, manufacturing and marketing of new medicinal products using biotechnology.
More information on EBE is available on the EBE website at http://ebe-biopharma.eu/.
Livia Le Métayer
Office Manager European Biopharmaceutical Enterprises
+32 2 626 25 61